نتائج البحث - "Bart A. van de Wiel"

1

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma

المؤلفون: Irene L. M. Reijers, Alexander M. Menzies, Alexander C. J. van Akkooi, Judith M. Versluis, Noëlle M. J. van den Heuvel, Robyn P. M. Saw, Thomas E. Pennington, Ellen Kapiteijn, Astrid A. M. van der Veldt, Karijn P. M. Suijkerbuijk, Geke A. P. Hospers, Elisa A. Rozeman, Willem M. C. Klop, Winan J. van Houdt, Karolina Sikorska, Jos A. van der Hage, Dirk J. Grünhagen, Michel W. Wouters, Arjen J. Witkamp, Charlotte L. Zuur, Judith M. Lijnsvelt, Alejandro Torres Acosta, Lindsay G. Grijpink-Ongering, Maria Gonzalez, Katarzyna Jóźwiak, Carolien Bierman, Kerwin F. Shannon, Sydney Ch’ng, Andrew J. Colebatch, Andrew J. Spillane, John B. A. G. Haanen, Robert V. Rawson, Bart A. van de Wiel, Lonneke V. van de Poll-Franse, Richard A. Scolyer, Annelies H. Boekhout, Georgina V. Long, Christian U. Blank

المساهمون: Medical and Clinical Psychology, Oral and Maxillofacial Surgery, Medical Oncology, Radiology & Nuclear Medicine, Surgery, Guided Treatment in Optimal Selected Cancer Patients (GUTS)

المصدر: Nature Medicine, 28(6), 1178-+. NATURE PORTFOLIO
Nature Medicine, 28(6), 1178-1188. Nature Publishing Group
Nature Medicine
Nature medicine, 28(6), 1178-1188. Nature Publishing Group
Nature Medicine, 28. Nature Publishing Group

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67d79d3cfe1f3c168f561afa30efdc6cTest
https://doi.org/10.1038/s41591-022-01851-xTest

2

Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma

المؤلفون: Bart A. van de Wiel, Judith M. Versluis, Robyn P. M. Saw, Sydney Ch'ng, C. Blank, Bastian Schilling, Irene L.M. Reijers, Richard A. Scolyer, Georgina V. Long, Michel W.J.M. Wouters, Alexander C.J. van Akkooi, Elisa A. Rozeman, Alexander M. Menzies

المصدر: European Journal of Cancer. 148:51-57

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Ipilimumab, Metastasis, Neoplasms, Multiple Primary, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Melanoma, Lymph node, Neoadjuvant therapy, Aged, Neoplasm Staging, Retrospective Studies, business.industry, Middle Aged, medicine.disease, Neoadjuvant Therapy, Survival Rate, Clinical trial, Nivolumab, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Female, Lymphadenectomy, Neoplasm Recurrence, Local, business, Follow-Up Studies, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0cd6cfcc041a55a4244871ca4c62202Test
https://doi.org/10.1016/j.ejca.2021.02.012Test

3

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

المصدر: Nature Medicine. 27:301-309

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::826ffd3ff8235e1e6c027f5367069a0cTest
https://doi.org/10.1038/s41591-020-01188-3Test

4

Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma

المؤلفون: Irene L. M. Reijers, Robert V. Rawson, Andrew J. Colebatch, Elisa A. Rozeman, Alex M. Menzies, Alexander C. J. van Akkooi, Kerwin F. Shannon, Michel W. Wouters, Robyn P. M. Saw, Winan J. van Houdt, Charlotte L. Zuur, Omgo E. Nieweg, Sydney Ch’ng, W. Martin C. Klop, Andrew J. Spillane, Georgina V. Long, Richard A. Scolyer, Bart A. van de Wiel, Christian U. Blank

المساهمون: Oral and Maxillofacial Surgery

المصدر: JAMA Surgery, 157(4), 335-342. AMER MEDICAL ASSOC
JAMA surgery, 157(4), 335-342. American Medical Association

مصطلحات موضوعية: Male, Skin Neoplasms, Pilot Projects, Middle Aged, Ipilimumab, Neoadjuvant Therapy, Nivolumab, Humans, Lymph Node Excision, Female, Surgery, Lymph Nodes, Prospective Studies, Neoplasm Recurrence, Local, Melanoma, Neoplasm Staging, Retrospective Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83255a1603596ffca3ab7f4e60dc4be4Test
https://doi.org/10.1001/jamasurg.2021.7554Test

5

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

المصدر: Nature Medicine. 24:1655-1661

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::296148c6d18ab7822871b24bd03c1594Test
https://doi.org/10.1038/s41591-018-0198-0Test

6

Abstract 3271: Different pathologic response rates between Australia and Europe in macroscopic stage III melanoma patients upon neoadjuvant ipilimumab plus nivolumab in the phase II OpACIN-neo trial

المؤلفون: Christian U. Blank, Kerwin F. Shannon, Bart A. van de Wiel, Irene L.M. Reijers, Andrew J. Spillane, María Jesús González González, Harm van Tinteren, Richard A. Scolyer, Elisa A. Rozeman, Johan Hansson, Karolina Sikorska, Hanna Eriksson, Alexander C.J. van Akkooi, Carolien Bierman, Alexander M. Menzies, Georgina V. Long, Judith M. Versluis, Robyn P. M. Saw

المصدر: Cancer Research. 80:3271-3271

مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, business.industry, Melanoma, Cancer, Ipilimumab, medicine.disease, Gastroenterology, Regimen, Oncology, Internal medicine, Cohort, medicine, Pathologic Response, Stage III melanoma, Nivolumab, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::8ce92f1132d4d004283bd3902be08e2dTest
https://doi.org/10.1158/1538-7445.am2020-3271Test

7

Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials

المصدر: Cancer Research. 80:3412-3412

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::64b9180c53a7818b8061f74aa4a507d6Test
https://doi.org/10.1158/1538-7445.am2020-3412Test

8

Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma

المصدر: Journal of Clinical Oncology. 38:10015-10015

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::f180171c2db0d6119a143cb5e06d49d3Test
https://doi.org/10.1200/jco.2020.38.15_suppl.10015Test

9

Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study

المصدر: Journal of Clinical Oncology. 38:TPS10087-TPS10087

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Ipilimumab, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, Pathologic Response, Interferon gamma, Stage III melanoma, Nivolumab, business, 030215 immunology, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::9636f93b3258fdc415785bc1248f34b3Test
https://doi.org/10.1200/jco.2020.38.15_suppl.tps10087Test

10

Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial

المؤلفون: Alexander M. Menzies, Ellen Kapiteijn, Alexander C.J. van Akkooi, Lars Bastholt, Christian U. Blank, Elisa A. Rozeman, Willem M.C. Klop, Bart A. van de Wiel, Irene L.M. Reijers, Andrew J. Spillane, Karijn P M Suijkerbuijk, Geke A. P. Hospers, Hanna Eriksson, James Larkin, Georgina V. Long, Inge Marie Svane, Henrik Schmidt, Astrid A M van der Veldt, Richard A. Scolyer

المصدر: Reijers, I, Rozeman, E A, Menzies, A M, De Wiel, B A V, Eriksson, H, Suijkerbuijk, K, Van Der Veldt, A A M, Kapiteijn, E, Hospers, G, Klop, W M C, Spillane, A, Scolyer, R A, Svane, I M, Bastholt, L, Schmidt, H, Larkin, J M G, Van Akkooi, A C J, Long, G V & Blank, C U 2019, ' Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial ', Journal of Clinical Oncology, vol. 37, no. 15 Suppl., TPS9605 . https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS9605Test

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c98b636b3dd00b5a364206cf1137b94Test
https://doi.org/10.1200/jco.2019.37.15_suppl.tps9605Test

تنقيح النتائج